
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Trevena Inc (TRVN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TRVN (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5
1 Year Target Price $5
0 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.11% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.24M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.4 | 52 Weeks Range 0.25 - 7.85 | Updated Date 08/16/2025 |
52 Weeks Range 0.25 - 7.85 | Updated Date 08/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -48.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1970.67% |
Management Effectiveness
Return on Assets (TTM) -62.39% | Return on Equity (TTM) -1014.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24343860 | Price to Sales(TTM) 0.44 |
Enterprise Value 24343860 | Price to Sales(TTM) 0.44 | ||
Enterprise Value to Revenue 44.59 | Enterprise Value to EBITDA 0.21 | Shares Outstanding 863788 | Shares Floating 858208 |
Shares Outstanding 863788 | Shares Floating 858208 | ||
Percent Insiders 0.48 | Percent Institutions 9.98 |
Upturn AI SWOT
Trevena Inc

Company Overview
History and Background
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders. Founded in 2007, Trevena has primarily focused on opioid-based drugs with reduced side effects.
Core Business Areas
- Pain Management: Trevena develops and commercializes pain management therapies, with a focus on biased ligands targeting G protein-coupled receptors (GPCRs).
Leadership and Structure
The leadership team includes Carrie Bourdow, the President and CEO. The company operates with a typical biopharmaceutical structure, involving research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Olinvyk (oliceridine): Olinvyk is an IV opioid approved for the management of acute pain in adults when alternative treatments are inadequate. Market share is small relative to established opioid analgesics. Competitors include morphine, fentanyl, hydromorphone, and other opioid-based pain medications from companies like Pfizer, Johnson & Johnson, and Mallinckrodt.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on pain management, is characterized by intense competition, stringent regulatory oversight, and evolving treatment paradigms including alternative pain therapies.
Positioning
Trevena aims to differentiate itself through biased ligand technology, seeking to offer pain relief with fewer side effects. This positions them as an innovator in the pain management space.
Total Addressable Market (TAM)
The total addressable market for acute pain management is substantial, estimated to be several billion USD annually. Trevena's positioning is focused on capturing a segment of this market with a safer opioid alternative.
Upturn SWOT Analysis
Strengths
- Novel biased ligand technology
- Olinvyk FDA approval
- Focused pipeline
Weaknesses
- Limited commercial resources
- Dependence on a single product (Olinvyk)
- History of operating losses
Opportunities
- Expansion of Olinvyk usage
- Partnerships for commercialization
- Development of additional biased ligand therapies
Threats
- Competition from established opioids
- Generic entry
- Regulatory changes impacting opioid prescribing
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- MNK
Competitive Landscape
Trevena's competitive advantage lies in its biased ligand technology. However, it faces significant competition from larger, more established pharmaceutical companies with broader portfolios and greater commercial reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal due to the development stage of the company and the recent launch of Olinvyk.
Future Projections: Future growth depends on successful commercialization of Olinvyk and potential pipeline development. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include commercialization efforts for Olinvyk and exploration of partnerships.
Summary
Trevena is a small biopharmaceutical company with a novel technology and an FDA-approved product, Olinvyk. It struggles with limited commercial resources and faces intense competition from established pharmaceutical giants. Future success hinges on Olinvyk's market adoption and pipeline development. Investors should watch for partnerships and cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevena Inc
Exchange NASDAQ | Headquaters Chesterbrook, PA, United States | ||
IPO Launch date 2014-01-31 | President, CEO & Chairman Ms. Carrie L. Bourdow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.trevena.com |
Full time employees 23 | Website https://www.trevena.com |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.